2012
Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia
Ruger JP, Chawarski M, Mazlan M, Ng N, Schottenfeld R. Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia. PLOS ONE 2012, 7: e50673. PMID: 23226534, PMCID: PMC3514172, DOI: 10.1371/journal.pone.0050673.Peer-Reviewed Original ResearchConceptsHeroin dependenceCost-effectiveness ratioSecondary outcomesOutcome measuresDrug usePlacebo-controlled clinical trialFirst heroin useIncremental cost-effectiveness ratioSocietal costsInjection drug useSecondary outcome measuresPrimary outcome measureIllicit opiate useIncremental treatment costNaltrexone treatmentPrimary outcomeMedication costsPlacebo interventionClinical trialsHeroin abstinenceOpiate useHeroin useBuprenorphineTreatment retentionNaltrexone
2011
Costs of Addressing Heroin Addiction in Malaysia and 32 Comparable Countries Worldwide
Ruger JP, Chawarski M, Mazlan M, Luekens C, Ng N, Schottenfeld R. Costs of Addressing Heroin Addiction in Malaysia and 32 Comparable Countries Worldwide. Health Services Research 2011, 47: 865-887. PMID: 22091732, PMCID: PMC3419893, DOI: 10.1111/j.1475-6773.2011.01335.x.Peer-Reviewed Original ResearchConceptsBuprenorphine treatmentOpioid dependence treatmentBlood testingDependence treatmentHeroin addictionHealth systemOpiate usersSimilar interventionsIncremental costLao People's Democratic RepublicPatientsHeroin problemTreatmentGreater percentagePeople's Democratic RepublicInterventionDemocratic RepublicMedicationsBuprenorphineNaltrexoneRCTs